



Sensor	Load 1	Load 2	Load 3
A2	TRL8605	ECD KIR2DL3	TRL8507
B2	TRL8605	ECD KIR2DL3	lirilumab-similar
C2	TRL8605	ECD KIR2DL3	Isotype control
D2	TRL8605	ECD KIR2DL3	Buffer

S3 Fig. Bio-Layer Interferometry (ForteBio Octet) was used to determine the competitive binding site for anti-KIR2DL3 mAbs. TRL8605 was first bound to the anti-Fc sensors (Load 1). KIR2DL3 added was then allowed to bind to TRL8605 (Load 2) followed by TRL8507 or lirilumab-similar (Load 3).